Nurix Therapeutics (Nasdaq: NRIX) reported Q1 2026 results and program milestones. Key clinical moves include ongoing Phase 2 DAYBreak CLL-201 to support Accelerated Approval, a planned Phase 3 DAYBreak CLL-306 to start midyear 2026, and a 2026 IND target for a tablet bexobrutideg in immunology.
Financials: revenue $6.3M, R&D $84.1M, net loss $87.2M, and cash and marketable securities $540.7M as of February 28, 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.